DNER and breast cancer: While BET inhibition has shown promising preclinical anticancer activity in BC, some early clinical studies have reported dose limiting toxicity of BETi, including thrombocytopenia and gastrointestinal disorders, indicating a need for the development of well tolerated BETi and/or optimization of dosing schemes and combinations (76).